At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 475 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
In Brief
A Phase 2 clinical trial evaluating Placebo and Erenumab for Migraine. Completed, enrolled 475 participants across 44 sites.
Detailed Summary
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by an open-label treatment phase (OLTP). To evaluate the effect of erenumab (AMG 334) compared to placebo on the change from baseline in monthly migraine days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartJan 2016
Primary CompletionSep 2017
Study CompletionJun 2019
TodayJul 2026
First PostedDec 15, 2015
Enrollment StartJan 6, 2016
Primary CompletionSep 25, 2017
Study CompletionJun 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.5 years ago
Interventions
Placebodrug
placebo via subcutaneous injection
Erenumabdrug
erenumab via subcutaneous injection
Erenumabdrug
erenumab via autoinjector (AI)/pen